Severe Alopecia Areata In Adolescents
INCYIncyte CorporationCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Olumiant/Baricitinib (JAK Inhibitor) in Severe Alopecia Areata In Adolescents. The expected timing is based on the latest available company guidance and may change.
02/27/26:- CHMP positive for adolescent severe AA. EU decision expected in months. US FDA decision expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.